Esaxerenone (CS-3150)

製品コードE0704 バッチE070401

印刷

化学情報

Synonyms

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₂₂H₂₁F₃N₂O₄S

分子量

466.48

CAS No.

1632006-28-0

Solubility (25°C)*

体外

DMSO

93 mg/mL (199.36 mM)

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Esaxerenone (CS-3150), a selective nonsteroidal mineralocorticoid receptor (MR) antagonist, binds to mineralocorticoid receptor and inhibits (3)H-aldosterone binding to mineralocorticoid receptor with an IC50 value of 9.4 nM. Esaxerenone (CS-3150) also has the property of increasing the likelihood of albuminuria returning to normal levels and reducing progression of albuminuria to higher levels.
in vitro	Esaxerenone is a selective nonsteroidal mineralocorticoid receptor antagonist, which inhibits aldosterone-induced transcriptional activation of human mineralocorticoid receptor with no agonistic effect on mineralocorticoid receptor, and has no antagonistic or agonistic effect on glucocorticoid receptor, androgen receptor and progesterone receptor even at the high concentration of 5 μM.^[1]
in vivo	In adrenalectomized rats, single oral administration of esaxerenone (CS-3150) suppressed aldosterone-induced decrease in urinary Na(+)/K(+) ratio, an index of in vivo mineralocorticoid receptor activation, and this suppressive effect is more potent and longer-lasting than that of spironolactone and eplerenone.^[1]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	293 A cells
	濃度	1 nM
	反応時間	24 h
	実験の流れ	For the transient transfection experiments, 293 A cells are inoculated on 100 mm dishes (4.5×10⁶ cells/dish) and cultured for 24 h in DMEM with 10% heat-inactivated FBS in 5% CO2 at 37 ℃. Then, the cells are co-transfected with each of expression plasmid and 3×GRE-Luc2P by lipofection using Lipofectamine 2000. After transfection, the cells are harvested and transferred into 96-well plates (1.0×10⁴ cells/well) containing a DMEM with 10% heat-inactivated charcoal-stripped FBS followed by incubation for 24 h. Serial dilutions of this compound with or without 1 nM of the corresponding ligands for each receptor are added and further incubated for approximately 24 h. The luciferase activity of each well is measured in a multimode assay system.
動物実験	動物モデル	bilateral adrenalectomized rat
	投薬量	0.3, 1 and 3 mg/kg
	投与方法	o.g.

参考

https://pubmed.ncbi.nlm.nih.gov/26073023/
https://pubmed.ncbi.nlm.nih.gov/33239409/

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。